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The search for an ideal cardiac valve replacement began in the earliestdays of cardiac surgery, and the commandments describing theessential characteristics of an ideal valve replacement device wereoutlined by Dwight Harken1 in the 1950s. These characteristicsinclude durability, absence of thrombogenicity, resistance to theability to provide normal hemodynamics, absence of damage to
blood elements, and technical practicality of insertion in a physiologic position in
the circulation. Additional desirable characteristics include resistance to infection
and lack of immunogenicity. If valves are to be used in children, the capacity for
growth must be included as well. Many prosthetic and bioprosthetic valves provide
good hemodynamic performance with low gradients and insignificant regurgitation.
However, no prosthetic valve will be able to meet the nonthrombogenicity criterion
because a nonthrombogenic, blood-compatible surface has not yet been developed.
All prosthetic and bioprosthetic valves remain more susceptible to infection than
native valves, a characteristic that is related to the microfilms that cover most
implanted prosthetic surfaces. Native valves are living structures that continuously
remodel and repair their structural proteins (collagen, elastin, and glycosamino
glycans), and because no current bioprosthetic valves contain living cells, these
valves predictably have limited durability. Debate continues over the value of living
cells in a homograft valve, but there is no evidence that homograft valves have
living interstitial cells that can carry out the remodeling and repair functions of a
normal valve. The work in the accompanying article demonstrates that both valve
endothelial and interstitial cells are capable of evoking an immune response in vitro
and support the concept that immune factors may prove to be important to long-term
homograft function. Because no currently available prosthetic, bioprosthetic, or
homograft valve fulfills all of these requirements, the search continues.
There is now increasing interest in trying to find ways to create a truly living
valve structure that will have a nonthrombogenic endothelial surface and a living
interstitium with repair and remodeling capabilities. Several groups, including our
own, are pursuing a tissue-engineering approach in which tissue constructs are
created from individual cellular components by seeding cells onto biodegradable
scaffolds2 or a matrix of decellularized allograft tissue.3 There have been some early
favorable results with these approaches in experimental animals,2,3 but many ques-
tions remain, including the following. What is the preferred scaffolding material on
which to have the cells organize, a biodegradable polymer or a decellularized native
valve matrix? What type of cells should be used to populate the matrix, and must
they be autologous? Can progenitor or stem cells circulating in the bloodstream
repopulate an acellular or decellularized matrix, or must the cells be cultured onto
scaffolds in vitro? Can these tissue-engineered structures remain viable, sustain the
wear and tear of the normal circulation over a lifetime, and grow in pediatric
patients? Will human cells cultured on scaffolds or a decellularized matrix behave
in the same way that cells from other mammalian species behave? The answers to
these and other questions are actively being addressed and will help to determine
whether the tissue-engineering approach will prove clinically applicable.
However, as we pursue the goal of an ideal valve replacement, the stimulus of
these attempts will also be likely to lead to a better understanding of the normal
architecture and biology of cardiac valves and of the abnormal developmental and
pathologic processes that affect them. The work in the accompanying article is an
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important example of this stimulus and effect. There is
clearly a process at work in which pursuit of a solution to a
clinical need leads to renewed interest in understanding
more basic aspects of normal and abnormal biology. This
effect is similar to the ways in which the development of the
surgical capability to address congenital heart disease in the
1940s and 1950s spurred renewed interest in the pathologic
anatomy of congenital heart disease. As a surgical investi-
gator in this era of the genetic revolution, I hope that we will
always remember the importance of a 2-way flow of infor-
mation and intellectual stimulation between basic science
and clinical science. Neither can or should proceed inde-
pendently of the influence of the other.
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